Unknown

Dataset Information

0

14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.

ABSTRACT: ErbB2, a metastasis-promoting oncoprotein, is overexpressed in approximately 25% of invasive/metastatic breast cancers, but in 50%-60% of noninvasive ductal carcinomas in situ (DCIS). It has been puzzling how a subset of ErbB2-overexpressing DCIS develops into invasive breast cancer (IBC). We found that co-overexpression of 14-3-3zeta in ErbB2-overexpressing DCIS conferred a higher risk of progression to IBC. ErbB2 and 14-3-3zeta overexpression, respectively, increased cell migration and decreased cell adhesion, two prerequisites of tumor cell invasion. 14-3-3zeta overexpression reduced cell adhesion by activating the TGF-beta/Smads pathway that led to ZFHX1B/SIP-1 upregulation, E-cadherin loss, and epithelial-mesenchymal transition. Importantly, patients whose breast tumors overexpressed both ErbB2 and 14-3-3zeta had higher rates of metastatic recurrence and death than those whose tumors overexpressed only one.

SUBMITTER: Lu J 

PROVIDER: S-EPMC2754239 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.

Lu Jing J   Guo Hua H   Treekitkarnmongkol Warapen W   Li Ping P   Zhang Jian J   Shi Bin B   Ling Chen C   Zhou Xiaoyan X   Chen Tongzhen T   Chiao Paul J PJ   Feng Xinhua X   Seewaldt Victoria L VL   Muller William J WJ   Sahin Aysegul A   Hung Mien-Chie MC   Yu Dihua D  

Cancer cell 20090901 3

ErbB2, a metastasis-promoting oncoprotein, is overexpressed in approximately 25% of invasive/metastatic breast cancers, but in 50%-60% of noninvasive ductal carcinomas in situ (DCIS). It has been puzzling how a subset of ErbB2-overexpressing DCIS develops into invasive breast cancer (IBC). We found that co-overexpression of 14-3-3zeta in ErbB2-overexpressing DCIS conferred a higher risk of progression to IBC. ErbB2 and 14-3-3zeta overexpression, respectively, increased cell migration and decreas  ...[more]

Similar Datasets

Unknown Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis.
| S-EPMC6032539 | biostudies-literature
Unknown Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition.
| S-EPMC7906203 | biostudies-literature
Unknown Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
| S-EPMC4047145 | biostudies-literature
Unknown Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
| S-EPMC5433063 | biostudies-literature
Unknown Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma.
| S-EPMC8162601 | biostudies-literature
Unknown Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
| S-EPMC4480702 | biostudies-literature
Transcriptomics Genomic alterations during the in situ to invasive ductal breast carcinoma transition shaped by the immune system
2020-12-01 | GSE144020 | GEO
Unknown Genomic Alterations during the <i>In Situ</i> to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System.
| S-EPMC8026652 | biostudies-literature
Transcriptomics Progression of ductal carcinoma in situ to invasive breast cancer
2012-03-31 | E-GEOD-33692 | biostudies-arrayexpress
Unknown SOX11 promotes invasive growth and ductal carcinoma in situ progression.
| S-EPMC5637904 | biostudies-literature